Therapy
Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial Kreiner, F. & Galbo, H. Arthritis Res. Ther. 12, R176 (2010)
Etanercept has been shown to have only modest beneficial effects when used for the treatment of polymyalgia rheumatica, according to the results of a small randomized, placebo-controlled trial. Patients who received etanercept (25 mg subcutaneously twice-weekly for 14 days) experienced a 24% reduction in disease activity score (P <0.05), but morning stiffness and patient-assessed pain did not decrease significantly.
Bone
A mouse study has shown that macrophage migration inhibitory factor (MIF) has an important role in fracture healing. Histomorphometric analyses showed that bone healing was markedly delayed in MIF-knockout mice, which was mainly attributable to slower osteoid mineralization within the fracture callus tissue.
Rheumatoid Arthritis
A case–control study performed at a hospital in Sweden found that patients with newly diagnosed rheumatoid arthritis and the presence of rheumatoid nodules had more extensive radiographic damage at 5 years compared with those without nodules. Bivariate analysis indicated that nodules, positivity for rheumatoid factor and antibodies against cyclic citrullinated peptide, and elevated disease activity score were strong baseline predictors for 5-year radiographic progression.
Bone
Daily intake of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 (2MD) has been shown to increase markers of bone formation in women with osteopenia. However, as bone mineral density did not increase significantly in these patients, it seems that 2MD might stimulate both bone formation and bone resorption, resulting in increased bone turnover.
Rights and permissions
About this article
Cite this article
In Brief. Nat Rev Rheumatol 6, 674 (2010). https://doi.org/10.1038/nrrheum.2010.190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.190